Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Valion Bio (TIVC) EPS (Basic) (2021 - 2025)

Valion Bio has reported EPS (Basic) over the past 5 years, most recently at -$1.97 for Q3 2025.

  • For Q3 2025, EPS (Basic) rose 49.87% year-over-year to -$1.97; the TTM value through Dec 2025 reached -$6.68, up 76.07%, while the annual FY2024 figure was -$19.68, 88.87% up from the prior year.
  • EPS (Basic) for Q3 2025 was -$1.97 at Valion Bio, up from -$2.19 in the prior quarter.
  • Over five years, EPS (Basic) peaked at -$0.23 in Q1 2022 and troughed at -$166.2 in Q4 2023.
  • A 5-year average of -$14.38 and a median of -$2.19 in 2025 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): tumbled 4861.7% in 2022 and later soared 99.12% in 2024.
  • Year by year, EPS (Basic) stood at -$0.47 in 2021, then plummeted by 4861.7% to -$23.32 in 2022, then plummeted by 612.69% to -$166.2 in 2023, then soared by 99.12% to -$1.46 in 2024, then tumbled by 34.93% to -$1.97 in 2025.
  • Business Quant data shows EPS (Basic) for TIVC at -$1.97 in Q3 2025, -$2.19 in Q2 2025, and -$2.52 in Q1 2025.